Regeneron Pharmaceuticals (NASDAQ:REGN) PT Lowered to $1,252.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price reduced by Royal Bank of Canada from $1,282.00 to $1,252.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price points to a potential upside of 21.91% from the company’s previous close.

Several other research firms have also commented on REGN. Canaccord Genuity Group reissued a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. JPMorgan Chase & Co. lifted their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. BMO Capital Markets restated an “outperform” rating and issued a $1,300.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Leerink Partners restated a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Finally, Argus lifted their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,118.62.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded down $65.00 on Tuesday, reaching $1,026.98. The stock had a trading volume of 762,223 shares, compared to its average volume of 474,239. The firm has a market capitalization of $113.16 billion, a PE ratio of 30.34, a PEG ratio of 3.93 and a beta of 0.12. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average of $1,131.94 and a 200 day moving average of $1,033.46. Regeneron Pharmaceuticals has a twelve month low of $769.19 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter last year, the firm earned $8.79 earnings per share. The business’s revenue was up 12.3% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The disclosure for this sale can be found here. Insiders have sold a total of 9,270 shares of company stock worth $10,695,833 in the last ninety days. Corporate insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Large investors have recently bought and sold shares of the business. Global Assets Advisory LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth $339,594,000. Capital International Investors lifted its position in Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after acquiring an additional 213,038 shares during the last quarter. First Trust Advisors LP lifted its position in Regeneron Pharmaceuticals by 115.2% during the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after acquiring an additional 195,902 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares during the last quarter. Finally, TD Asset Management Inc raised its position in shares of Regeneron Pharmaceuticals by 162.9% during the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after buying an additional 166,998 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.